USANA Health Sciences Announces Proposed Expansion of its Board of Directors
24 3월 2016 - 5:15AM
Business Wire
USANA Health Sciences, Inc. (NYSE: USNA) today announced that it
is proposing to shareholders the election of three new members to
its Board of Directors at its Annual Shareholder Meeting on May 2,
2016. The proposal would increase the size of the Board to seven
directors and expand the breadth of expertise, backgrounds and
viewpoints of the Board. David A. Wentz, Co-Chief Executive Officer
of the Company, Frederic J. Winssinger and Feng Peng have been
nominated by the Board to stand for election at the Annual
Shareholder Meeting. D. Richard Williams, who was appointed to the
Board in March 2016, will also stand for re-election at the Annual
Shareholder Meeting, along with Dr. Myron W. Wentz, Robert Anciaux
and Gilbert A. Fuller. Long time Board members Jerry G. McClain and
Ronald S. Poelman will retire from the Board when their current
terms expire at the 2016 Annual Meeting. Mr. McClain has served as
a director of USANA since June 2001, while Mr. Poelman has served
as a director since 1995.
Mr. Wentz was appointed Chief Executive Officer of USANA in July
2008 and became Co-Chief Executive Officer in August 2015. He has
held a number of other strategic positions with the Company since
its inception in 1992. Mr. Wentz’s addition to the Board will
expand the Board’s industry expertise and further unify the Board’s
partnership with management.
Mr. Winssinger has more than two decades of experience in the
financial markets, including serving as a portfolio manager in
London with JP Morgan Investment Management, Adelphi Capital,
Capital@Work, and, most recently, RW Partners, where he was the
managing partner. He is the founder and managing director of
PlanningCore Wealth Advisors in Phoenix, Arizona.
Mr. Peng has extensive business experience in China, financial
and corporate strategy expertise, and a strong information
technology background. Since 2013, Mr. Peng has served as the Chief
Financial Officer of Ossen Innovation Company, Ltd., a China-based
manufacturing company listed on the NASDAQ exchange. Prior to that,
he served as Senior Vice President at MZ Group, where he provided
strategic consulting services related to U.S. capital markets to
Chinese clients. Prior to working at MZ Group, he served in various
capacities at Thomson Financial and Citigroup.
Myron W. Wentz, Ph.D., Chairman of the Board, commented, “Ron’s
and Jerry’s expertise, wisdom and integrity have made immeasurable
contributions to the Board and USANA over the years. They have
played a significant role in our development into a global
nutrition company. On behalf of the Board, employees and
shareholders, we are grateful for their many years of service and
the significant contributions they have made. We wish them all the
best in their future endeavors.”
Wentz added, “We are delighted that Dave, Frederic and Feng have
accepted nominations to the USANA Board and agreed to serve USANA’s
shareholders. Their extensive industry, financial, and
international expertise will provide significant value to the USANA
Board and executive team.”
About USANA
USANA develops and manufactures high-quality nutritional
supplements, healthy foods and personal care products that are sold
directly to Associates and Preferred Customers throughout the
United States, Canada, Australia, New Zealand, Hong Kong, China,
Japan, Taiwan, South Korea, Singapore, Mexico, Malaysia, the
Philippines, the Netherlands, the United Kingdom, Thailand, France,
Belgium, Colombia and Indonesia. More information on USANA can be
found at http://www.usanahealthsciences.com.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20160323006529/en/
USANA Health Sciences, Inc.Investors contact:Patrique Richards,
801-954-7961Investor
Relationsinvestor.relations@us.usana.comorMedia contact:Dan Macuga,
801-954-7280Public Relations
USANA Health Sciences (NYSE:USNA)
과거 데이터 주식 차트
부터 6월(6) 2024 으로 7월(7) 2024
USANA Health Sciences (NYSE:USNA)
과거 데이터 주식 차트
부터 7월(7) 2023 으로 7월(7) 2024